Paradigm Biopharmaceuticals Ltd (ASX:PAR) has repurposed an anti-inflammatory drug called pentosan polysulphate sodium (PPS) to treat multiple new indications, including Osteoarthritis.
The share price of Paradigm Biopharmaceuticals Ltd (ASX: PAR) is down today on an update of its new drug application. What does this mean for the Paradigm share price?
Making ASX 200 news today was Paradigm Biopharmaceuticals Ltd (ASX:PAR), QBE Insurance Group Ltd (ASX:QBE) and Brambles Limited (ASX:BXB).
The Paradigm Biopharmaceuticals (ASX: PAR) share price was trading 1.4% lower today following the release of its half-year financial report on Friday afternoon.
